Medytox Affiliate Nyumeko Holds "2026 Kickoff Meeting"

“Aiming to Set a New All-Time Record for Annual Sales”

Medytox affiliate Nyumeko announced on the 10th that it held a kickoff meeting to achieve this year’s business targets, where it shared its business plan and strategic direction aimed at setting a new record for all-time highest sales.

Nyumeko plans to enhance employees’ professional capabilities by invigorating internal training in order to further increase the domestic and overseas market share of the next-generation botulinum toxin product “Newlux.” The company has also set out a policy to continue expanding into additional overseas markets while carrying out differentiated promotional activities at major academic conferences.

At the '2026 NewMeco Kickoff Meeting' held at the Ditox Global Business Center, Lee Sangyun, CEO of NewMeco, is explaining the business plan and strategic direction. Medytox

The company has also drawn up marketing strategies to accelerate sales of Medytox’s flagship products. Nyumeko plans to expand customized academic events such as in-house educational programs and seminars tailored to each region and network, as well as invited lectures and award ceremonies, as collaboration programs targeting major key opinion leaders (KOLs), in order to strengthen the premium positioning of the botulinum toxin product “Coretox.” In particular, to broaden brand awareness of the new hyaluronic acid filler products “Neuramis Heart” and “Neuramis Skin Enhancer,” which were launched last year under the “Neuramis” line, the company is preparing online advertisements linked to major hospitals’ social media (SNS) channels that reflect consumer needs and seasonal characteristics.

At the event, Nyumeko CEO Lee Sangyun said, “Last year, thanks to the expansion of sales outlets for ‘Coretox’ and the aggressive marketing of ‘Neuramis,’ we exceeded our sales targets,” adding, “We will set a new annual sales record again by leveraging our overwhelming sales capabilities and solid network.” He went on to say, “We will defend our No. 1 market share in the domestic toxin and filler markets, and by focusing on overseas exports of ‘Newlux,’ we will lay the groundwork for a global leap forward.”

Meanwhile, since 2013 Nyumeko has been responsible for domestic distribution of Medytox’s botulinum toxin products and fillers, and since the 2023 launch of the next-generation botulinum toxin product “Newlux,” it has been rapidly expanding its presence not only in Korea but also in overseas markets including Europe, Central and South America, and Asia.

This content was produced with the assistance of AI translation services.